849 assets in Breast Cancer

Therapeutic assets addressing Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cetuximab Breast Cancer	Pfizer	P2	B (61)
Dehydroepiandrosterone Breast Cancer	European Institute of Oncology	P4	B (61)
Disitamab Vedotin Breast Cancer	Fudan University	P4	B (61)
Etoposide Breast Cancer	Fudan University	P3	B (61)
Indocyanine Green Breast Cancer	Isabelle Henskens	P3	B (61)
Megestrol Acetate Breast Cancer	Sun Yat-sen University	P3	B (61)
Memantine Breast Cancer	UNC Lineberger Comprehensive Cancer Center	P3	B (61)
Nepenthe Breast Cancer	Antalya Training and Research Hospital	P4	B (61)
Raloxifene Breast Cancer	Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	P3	B (61)
Samuraciclib Breast Cancer	Pfizer	P2	B (61)
(±)-Tramadol Breast Cancer	Aga Khan University	P4	B (61)
4H-1-BENZOPYRAN-4-ONE, 7-((6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-2,3-DIHYDO-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-, (S)- Breast Cancer	Alexandria University	P4	B (60)
Abiraterone Breast Cancer	M.D. Anderson Cancer Center	P3	B (60)
Alectinib Breast Cancer	OHSU Knight Cancer Institute	P2	B (60)
Aspirin Breast Cancer	The Christie NHS Foundation Trust	P3	B (60)
Autologous Conditioned Plasma Breast Cancer	University of Miami	P2	B (60)
Binimetinib Breast Cancer	National Cancer Institute (NCI)	P2	B (60)
bnt327 Breast Cancer	BioNTech SE	P2	B (60)
Camustine Breast Cancer	General Oncology, Inc.	P3	B (60)
CD47/SIRPA-BLOCKING AGENT ALX148 Breast Cancer	ALX Oncology Inc.	P2	B (60)
Celecoxib Breast Cancer	Cairo University	P3	B (60)
Ceralasertib Breast Cancer	National Cancer Institute (NCI)	P2	B (60)
Cimetidine Breast Cancer	Ohio State University Comprehensive Cancer Center	P2/3	B (60)
Dalpiciclib Isetionate Breast Cancer	Shandong Suncadia Medicine Co., Ltd.	P3	B (60)
Estrogens, Conjugated Breast Cancer	University of Kansas Medical Center	P3	B (60)
Famitinib Breast Cancer	Fudan University	P3	B (60)
Furosemide Breast Cancer	European Organisation for Research and Treatment of Cancer - EORTC	P3	B (60)
Hyaluronidase Zzxf Breast Cancer	Baylor Breast Care Center	P2	B (60)
Inavolisib Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	B (60)
Ipatasertib Breast Cancer	German Cancer Research Center	P3	B (60)
Melatonin Breast Cancer	Mansoura University	P2/3	B (60)
Melphalan Breast Cancer	Delcath Systems Inc.	P3	B (60)
men1611 Breast Cancer	MedSIR	P2	B (60)
Minoxidil Breast Cancer	Ohio State University Comprehensive Cancer Center	P2	B (60)
Neratinib Breast Cancer	Xijing Hospital	P3	B (60)
Osimertinib Breast Cancer	OHSU Knight Cancer Institute	P2	B (60)
Prednisone Breast Cancer	M.D. Anderson Cancer Center	P3	B (60)
Pumvc3-Igfbp2-Her2-Igf1R Plasmid Dna Vaccine Breast Cancer	University of Washington	P2	B (60)
Rph-051 Breast Cancer	R-Pharm	P3	B (60)
Salovum Breast Cancer	Henrik Lindman	P3	B (60)
Sargramostim Breast Cancer	University of Washington	P3	B (60)
Testosterone Undecylate Breast Cancer	Aminex Therapeutics, Inc.	P3	B (60)
Varinon Breast Cancer	Alexandria University	P4	B (60)
Vemurafenib Breast Cancer	OHSU Knight Cancer Institute	P2	B (60)
Ala-Cys-Ser-Ala-Pro-Arg-Tyr-Cys-Tyr-Gln-Lys-Pro-Pro-Tyr-His Cyclic (2->9)-Disulfide Breast Cancer	MedSIR	P3	B (59)
Bebt-209 Capsules Breast Cancer	BeBetter Med Inc	P3	B (59)
esg401 Breast Cancer	Qilu Pharmaceutical Co., Ltd.	P3	B (59)
Fludarabine Breast Cancer	Vall d'Hebron Institute of Oncology	P3	B (59)
Lasofoxifene Breast Cancer	LeonaBio	P3	B (59)
Loperamide Breast Cancer	Maryam Lustberg	P2/3	B (59)

Showing 101 to 150 of 849 assets

PreviousPage 3 of 17Next